EV charging stations and RES-based DG: A centralized approach for smart integration in active distribution grids

Renewable Energy Sources based (RES-based) Dispersed Generation (DG) and Electrical Vehicles (EVs) charging systems diffusion is in progress in many Countries around the word. They have huge effects on the distribution grids planning and operation, particularly on MV and LV distribution grids. Many studies on their impact on the power systems are ongoing, proposing different approaches of managing. The present work deals with a real application case of integration of EVs charging stations with ES-based DG. The final task of the integration is to be able to assure the maximum utilization of the distribution grid to which both are connected, without any upgrading action, and in accordance with Distribution System Operators (DSOs) needs. The application of the proposed approach is related to an existent distribution system, owned by edistribuzione, the leading DSO in Italy. Diverse types of EVs supplying stations, with diverse diffusion scenarios, have been assumed for the case study; various Optimal Power Flow (OPF) models, based on diverse objective functions, reflecting DSO necessities, have been applied and tried. The obtained results demonstrate that a centralized management approach by the DSO, could assure the respect of operation limits of the system in the actual asset, delaying or avoiding upgrading engagements and charges

Is acting prosocially beneficial for the credit market?

This article argues that behaving prosocially implies more transparent information during the negotiation process of a financial contract and more cooperation among the parties to respect the terms of the contract. For this reason this work considers interest rate on loans and insolvency rate functions of prosocial behaviour along with the traditional socio-economic and financial collaterals. The context of study is Italy and the analysis is developed at a cross-regional level. We collect data from the two reports on “Relatives and Safety Net” produced by the Italian Centre Bureau of Statistics (ISTAT) in 1998 and 2003 and from the reports on “Regional Economics” produced by the Bank of Italy in the same years. A two-period panel model shows two interesting outcomes. Firstly, regions with a higher proportion of prosocial individuals report lower interest rates on loans and insolvency rates. Secondly, when we include the efficiency of legal enforcement, evidence supports the idea that a more efficient legal framework can act as a more reliable transmission mechanism of institutional norms and facilitate the internalisation of social norms

European Perceptions of Autonomous and Robotized Cars

This article explores users\u2019 attitudes, perceptions, views, and emotions toward car automation and robotization, two processes increasingly affecting society in different ways\u2013\u2013namely, the rise of autonomous and robotized cars (and vehicles in general) and the increasing level of robotization of current cars. To address these questions, we investigated the feeling of trust and comfort toward driverless cars among Europeans using two Eurobarometer surveys. Making use of two representative samples of the European population, we aimed to explore citizens\u2019 attitudes and opinions about automation and digitization. The two surveys involved, respectively, 27,801 and 27,901 participants from all EU-28 countries. Furthermore, we investigated, in Northern Italy, the perception of robotization of cars and other technologies of everyday use, as well as the attitudes and opinions of children and preteens (n = 740), and adolescents (n = 801)\u2014 relevant social groups not covered in the Eurobarometer surveys

European perceptions of autonomous and robotized cars

open3noThis article explores users’ attitudes, perceptions, views, and emotions toward car automation and robotization, two processes increasingly affecting society in different ways––namely, the rise of autonomous and robotized cars (and vehicles in general) and the increasing level of robotization of current cars. To address these questions, we investigated the feeling of trust and comfort toward driverless cars among Europeans using two Eurobarometer surveys. Making use of two representative samples of the European population, we aimed to explore citizens’ attitudes and opinions about automation and digitization. The two surveys involved, respectively, 27,801 and 27,901 participants from all EU-28 countries. Furthermore, we investigated, in Northern Italy, the perception of robotization of cars and other technologies of everyday use, as well as the attitudes and opinions of children and preteens (n = 740), and adolescents (n = 801)— relevant social groups not covered in the Eurobarometer surveys.openFortunati, L., Lugano, G., Manganelli, A.M.Fortunati, L.; Lugano, G.; Manganelli, A. M

Local and regional scale biodiversity patterns of forest snail assemblages in Tuscany (central Italy)

The land mollusc faunas of three forest areas of Tuscany (central Italy) were sampled to test the effect of geographical and environmental factors on the structure of biodiversity. A total of 60 sites were surveyed in the years 2009-2011, recording species richness and abundance of snails in 400 m2 plots randomly selected in beech and oak woods. Sampling strategy relied on a combination of visual search and litter analysis. Environmental variables (topsoil pH and altitude) and UTM coordinates were recorded to detect relationships with species richness and number of individuals per plot. Abundance data were analyzed using non-metric multidimensional scaling and canonical correspondence analysis; faunal similarity within and between areas was computed by the Bray Curtis index and snail assemblages of the two forest types were compared. A total of 55 species were recorded, with low values of local richness and abundance per site compared to other forest sites in central and northern Europe. Total richness was similar in the three areas, but composition and local richness varied significantly between them. Geographical factors explained the highest percentage of variance, while habitat type, altitude and pH only accounted for a minor part. Internal similarity was greater than between-area similarity in two out of three areas. Beech forests had richer and more heterogeneous faunas, but lower levels of abundance than oak woods. The results are discussed in terms of historical biogeography and local environmental conditions, and compared with those from similar surveys across Europe

Monacha samsunensis (Pfeiffer, 1868): another Anatolian species introduced to Western Europe, where it is known as Monacha atacis Gittenberger & de Winter, 1985 (Gastropoda: Eupulmonata: Hygromiidae)

Populations of Monacha atacis from southern Occitania in France and of M. samsunensis from northern Anatolia in Turkey (Atakum/Samsun and Kastamonu) were investigated by an integrative approach based on morphological (shell and genitalia) and molecular (mitochondrial and nuclear gene sequences) features. Morphological examination revealed a complex pattern of variation within and between geographically separated populations, while molecular analysis showed strong similarity between the two species, confirming earlier suggestions that the species are conspecific. Pfeiffer’s name Helix samsunensis introduced in 1868 has priority over the name M. atacis given by Gittenberger & de Winter in 1985. © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

Pharmacological treatment for familial amyloid neuropathy

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess and compare the efficacy, acceptability, and tolerability of pharmacologic disease‐modifying agents for familial amyloid neuropathy (FAP)

Pharmacological treatment for familial amyloid polyneuropathy

Background: Disease‐modifying pharmacological agents for transthyretin (TTR)‐related familial amyloid polyneuropathy (FAP) have become available in the last decade, but evidence on their efficacy and safety is limited. This review focuses on disease‐modifying pharmacological treatment for TTR‐related and other FAPs, encompassing amyloid kinetic stabilisers, amyloid matrix solvents, and amyloid precursor inhibitors. Objectives: To assess and compare the efficacy, acceptability, and tolerability of disease‐modifying pharmacological agents for familial amyloid polyneuropathies (FAPs). Search methods: On 18 November 2019, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase. We reviewed reference lists of articles and textbooks on peripheral neuropathies. We also contacted experts in the field. We searched clinical trials registries and manufacturers' websites. Selection criteria: We included randomised clinical trials (RCTs) or quasi‐RCTs investigating any disease‐modifying pharmacological agent in adults with FAPs. Disability due to FAP progression was the primary outcome. Secondary outcomes were severity of peripheral neuropathy, change in modified body mass index (mBMI), quality of life, severity of depression, mortality, and adverse events during the trial. Data collection and analysis: We followed standard Cochrane methodology. Main results: The review included four RCTs involving 655 people with TTR‐FAP. The manufacturers of the drugs under investigation funded three of the studies. The trials investigated different drugs versus placebo and we did not conduct a meta‐analysis. One RCT compared tafamidis with placebo in early‐stage TTR‐FAP (128 randomised participants). The trial did not explore our predetermined disability outcome measures. After 18 months, tafamidis might reduce progression of peripheral neuropathy slightly more than placebo (Neuropathy Impairment Score (NIS) in the lower limbs; mean difference (MD) ‐3.21 points, 95% confidential interval (CI) ‐5.63 to ‐0.79; P = 0.009; low‐certainty evidence). However, tafamidis might lead to little or no difference in the change of quality of life between groups (Norfolk Quality of Life‐Diabetic Neuropathy (Norfolk QOL‐DN) total score; MD ‐4.50 points, 95% CI ‐11.27 to 2.27; P = 0.19; very low‐certainty evidence). No clear between‐group difference was found in the numbers of participants who died (risk ratio (RR) 0.65, 95% CI 0.11 to 3.74; P = 0.63; very low‐certainty evidence), who dropped out due to adverse events (RR 1.29, 95% CI 0.30 to 5.54; P = 0.73; very low‐certainty evidence), or who experienced at least one severe adverse event during the trial (RR 1.16, 95% CI 0.37 to 3.62; P = 0.79; very low‐certainty evidence). One RCT compared diflunisal with placebo (130 randomised participants). At month 24, diflunisal might reduce progression of disability (Kumamoto Score; MD ‐4.90 points, 95% CI ‐7.89 to ‐1.91; P = 0.002; low‐certainty evidence) and peripheral neuropathy (NIS plus 7 nerve tests; MD ‐18.10 points, 95% CI ‐26.03 to ‐10.17; P < 0.001; low‐certainty evidence) more than placebo. After 24 months, changes from baseline in the quality of life measured by the 36‐Item Short‐Form Health Survey score showed no clear difference between groups for the physical component (MD 6.10 points, 95% CI 2.56 to 9.64; P = 0.001; very low‐certainty evidence) and the mental component (MD 4.40 points, 95% CI ‐0.19 to 8.99; P = 0.063; very low‐certainty evidence). There was no clear between‐group difference in the number of people who died (RR 0.46, 95% CI 0.15 to 1.41; P = 0.17; very low‐certainty evidence), in the number of dropouts due to adverse events (RR 2.06, 95% CI 0.39 to 10.87; P = 0.39; very low‐certainty evidence), and in the number of people who experienced at least one severe adverse event (RR 0.77, 95% CI 0.18 to 3.32; P = 0.73; very low‐certainty evidence) during the trial. One RCT compared patisiran with placebo (225 randomised participants). After 18 months, patisiran reduced both progression of disability (Rasch‐built Overall Disability Scale; least‐squares MD 8.90 points, 95% CI 7.00 to 10.80; P < 0.001; moderate‐certainty evidence) and peripheral neuropathy (modified NIS plus 7 nerve tests ‐ Alnylam version; least‐squares MD ‐33.99 points, 95% CI ‐39.86 to ‐28.13; P < 0.001; moderate‐certainty evidence) more than placebo. At month 18, the change in quality of life between groups favoured patisiran (Norfolk QOL‐DN total score; least‐squares MD ‐21.10 points, 95% CI ‐27.20 to ‐15.00; P < 0.001; low‐certainty evidence). There was little or no between‐group difference in the number of participants who died (RR 0.61, 95% CI 0.21 to 1.74; P = 0.35; low‐certainty evidence), dropped out due to adverse events (RR 0.33, 95% CI 0.13 to 0.82; P = 0.017; low‐certainty evidence), or experienced at least one severe adverse event (RR 0.91, 95% CI 0.64 to 1.28; P = 0.58; low‐certainty evidence) during the trial. One RCT compared inotersen with placebo (172 randomised participants). The trial did not explore our predetermined disability outcome measures. From baseline to week 66, inotersen reduced progression of peripheral neuropathy more than placebo (modified NIS plus 7 nerve tests ‐ Ionis version; MD ‐19.73 points, 95% CI ‐26.50 to ‐12.96; P < 0.001; moderate‐certainty evidence). At week 65, the change in quality of life between groups favoured inotersen (Norfolk QOL‐DN total score; MD ‐10.85 points, 95% CI ‐17.25 to ‐4.45; P < 0.001; low‐certainty evidence). Inotersen may slightly increase mortality (RR 5.94, 95% CI 0.33 to 105.60; P = 0.22; low‐certainty evidence) and occurrence of severe adverse events (RR 1.48, 95% CI 0.85 to 2.57; P = 0.16; low‐certainty evidence) compared to placebo. More dropouts due to adverse events were observed in the inotersen than in the placebo group (RR 8.57, 95% CI 1.16 to 63.07; P = 0.035; low‐certainty evidence). There were no studies addressing apolipoprotein AI‐FAP, gelsolin‐FAP, and beta‐2‐microglobulin‐FAP. Authors' conclusions Evidence on the pharmacological treatment of FAPs from RCTs is limited to TTR‐FAP. No studies directly compare disease‐modifying pharmacological treatments for TTR‐FAP. Results from placebo‐controlled trials indicate that tafamidis, diflunisal, patisiran, and inotersen may be beneficial in TTR‐FAP, but further investigations are needed. Since direct comparative studies for TTR‐FAP will be hampered by sample size and costs required to demonstrate superiority of one drug over another, long‐term non‐randomised open‐label studies monitoring their efficacy and safety are needed